Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
124.04B
Market cap124.04B
Price-Earnings ratio
16.98
Price-Earnings ratio16.98
Dividend yield
4.13%
Dividend yield4.13%
Average volume
10.73M
Average volume10.73M
High today
$62.29
High today$62.29
Low today
$60.47
Low today$60.47
Open price
$60.88
Open price$60.88
Volume
12.26M
Volume12.26M
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $60.79. The company's market cap stands at 124.04B, with a P/E ratio of 16.98 and a dividend yield of 4.13%.

On 2026-07-18, Bristol-Myers Squibb(BMY) stock traded between a low of $60.47 and a high of $62.29. Shares are currently priced at $60.79, which is +0.5% above the low and -2.4% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 12.26M, against a daily average of 10.73M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $62.89 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $62.89 and a 52-week low of $42.52.

BMY News

Simply Wall St 1d
Is Bristol-Myers Squibb Reasonable After Its 32% Run?

Bristol-Myers Squibb stock has delivered a 31.9% return over the past year, yet its current valuation checks paint a mixed picture rather than a clear bargain o...

Is Bristol-Myers Squibb Reasonable After Its 32% Run?
Benzinga 5d
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

The agency assigned a Prescription Drug User Fee Act target action date of May 13, 2027, with the filing supported by positive Phase 3 SUCCESSOR-2 trial results...

Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

Analyst ratings

61%

of 31 ratings
Buy
35.5%
Hold
61.3%
Sell
3.2%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.